Analysts Set Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Price Target at $43.40

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) has earned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $43.40.

Several brokerages have commented on DMRA. Guggenheim restated a “buy” rating and issued a $40.00 price objective (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. Evercore started coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 price objective for the company. UBS Group started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. They issued a “buy” rating and a $45.00 price target for the company. Lifesci Capital upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, February 2nd. Finally, Royal Bank Of Canada started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They issued an “outperform” rating and a $40.00 price target for the company.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of NASDAQ DMRA opened at $25.30 on Monday. Damora Therapeutics, Inc. Common Stock has a 12 month low of $2.45 and a 12 month high of $38.33. The firm has a market capitalization of $1.56 billion, a PE ratio of -4.53 and a beta of 1.50. The firm has a fifty day simple moving average of $25.19 and a two-hundred day simple moving average of $24.79.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.23). On average, sell-side analysts predict that Damora Therapeutics, Inc. Common Stock will post -0.95 earnings per share for the current year.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $40,000. Virtu Financial LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at about $49,000. Two Sigma Investments LP purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at about $76,000. Connective Capital Management LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at about $100,000. Finally, Geode Capital Management LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $266,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.